Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of MDR-001 in Hepatic Impairment
NCT07550634Phase 1Not yet recruiting
- Sponsor
- MindRank
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MDR-001 in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by MindRank. Primary endpoint: Primary Pharmacokinetic Parameters (AUC and Cmax) at 48 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
MDR-001
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07550634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550634.